Bullish View On Netflix; Akebia Therapeutics Misses Q2 Expectations
- August 25th, 2023
- 505 views
Netflix, Inc. (Nasdaq: NFLX), a prominent streaming entertainment service, was upgraded from Hold to Buy by Loop Capital, accompanied by a revised price target increase from $425 to $500.
With $NFLX closing at $406.93 on Thursday, this updated price target suggests a potential upside of $93.07 or roughly 22.88%, based on the brokerage and advisory firm's analysis.
In other news, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a pharmaceutical company, reported a second-quarter 2023 loss of $(0.06) per share, falling short of the consensus estimate loss of $(0.02). The company's quarterly sales totaled $56.38 million, slightly below analysts' projected revenue of $59.10 million for the period.
$AKBA was trading at $1.21 in pre-market, down $0.04 (-3.19%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login